NA-Selank

NA-Selank (N-Acetyl Selank) is a modified version of Selank in which an acetyl group has been added to improve resistance to enzymatic breakdown and extend its duration of activity. It is positioned in research and vendor literature as a longer-acting alternative to standard Selank, intended to produce similar anxiolytic and mild nootropic effects with less frequent dosing. Independent published research specifically on the N-acetylated form is considerably more limited than for Selank itself, so much of its proposed profile is extrapolated from the parent compound. It is not approved for medical use and is available only as a research compound. Reported benefits include proposed longer duration of action compared with standard selank, explored for anxiolytic effects without apparent sedation, studied to a limited extent for mild nootropic and stress-modulating effects.

Reported ranges run 250-750 mcg. A low protocol is 250 mcg every other day, and a high protocol is 750 mcg once daily. This is reference information, not a dosing recommendation.

Reported to be longer than standard Selank due to the acetyl modification, though precise human pharmacokinetic values have not been well characterized.. That is what sets the dosing frequency, and it is why the timing guidance is morning.

Subcutaneous: into fat, under the skin. Historically discussed as an extended-duration analog of an intranasally-used parent compound; this profile reflects subcutaneous injection as used in current research contexts.

4-6 weeks on, followed by 2-4 weeks off. Cycling recommendations are extrapolated from parent-compound research rather than dedicated studies.

Reported side effects include injection site irritation, mild headache reported anecdotally, limited independent safety data specific to the acetylated form, uncertain long-term effects given sparse research. Evidence level for this compound is moderate evidence.